Call Support +91-85588-96644
TCYonline

Login

Sign Up

Please enter a Username or Email ID
Please enter a password
Keep me logged in
Please enter your name
Please enter your mobile number
You can't leave Captcha Code empty
By submitting this form, you agree to the Terms & Privacy Policy.
OR

Sign Up via Facebook

Sign Up via Google

Sign Up via Twitter

Download Software
Tests given

Download TCY App

App Image
 
loading

GENDER/ HEALTH/ EDUCATION - August 2026

Aug 2026

Aug 01, 2026

FSSAI suspends Dior Pharmaceuticals’ nutraceutical licence in Punjab

The Food Safety and Standards Authority of India (FSSAI) suspended the nutraceutical manufacturing licence of Dior Pharmaceuticals in Punjab in July 2026. An inspection found serious violations of manufacturing and hygiene standards, along with deficiencies in Good Manufacturing Practices at the plant. The suspension may affect production schedules and lead to audits or further regulatory action if violations persist. Dior Pharmaceuticals must address the concerns, implement corrective measures and reapply for licensure through a formal process. The case highlights stronger regulatory oversight of nutraceutical facilities in India and may prompt other firms to review their quality control, supplier management and hygiene practices.
  • FSSAI suspended the licence in July 2026 after inspection.
  • Violations include manufacturing and hygiene standards and GMP deficiencies.
  • Suspension could affect production and trigger further actions.
  • Company must address concerns and reapply for licensure.
  • Signals stricter nutraceutical sector enforcement in India.
Share on
Keep Yourself updated on Latest PTE Exam Pattern

Avail Free Topic-wise Tests and various other offers.